Marginal zone lymphomas (MZLs) are a group of indolent (slow-growing) B-cell non-Hodgkin lymphomas (NHLs) beginning in a part of lymph tissue called the marginal zone, which account for approximately five to ten percent of all NHL cases.

The average age at diagnosis is about 60 years, and they are slightly more common in women than in men.

**TYPES OF MZL**

**Mucosa-associated lymphoid tissue (MALT) lymphoma** is the most common form of MZL. MALT lymphomas usually arise in organs that are devoid of lymphoid tissue. MALT lymphomas that are most commonly found in the stomach are called gastric MALT. MALT lymphomas can also be found in other organs thus called non-gastric MALT and can frequently affect other regions of the body such as the small intestine, salivary glands, thyroid, breast, around the eye (ocular adnexa lymphoma [OAL]), lung and skin. Very frequently MALT lymphomas arise secondary to chronic inflammation that can be caused secondary to microbial agents such as bacteria or viruses, or can even be caused due to chronic inflammation caused by autoimmune conditions such as Hashimoto’s thyroiditis or Sjogren’s syndrome. Some of the microorganisms that have been shown to cause MALT lymphoma include chronic infection with *Helicobacter pylori* which has been implicated in chronic inflammation of the stomach region causing gastritis.,

**Mediterranean abdominal lymphoma,** also known as immunoproliferative small intestinal disease, is a type of MALT lymphoma that affects young adults in eastern Mediterranean countries. Most cases originate in the abdomen and occur in patients infected with *Campylobacter jejuni*.

**Nodal MZL,** is a rare type of MZL that occurs within the lymph nodes.

**Splenic MZL** occurs most often in the spleen, blood, and bone marrow. It has been associated with hepatitis C virus (HCV) infection.

**TREATMENT OPTIONS**

Treatment selection for a patient with MZL depends on the type, the stage and location of the disease, the patient’s age and overall health, and any lymphoma-related signs or symptoms.

**GASTRIC MALT LYMPHOMAS**

Since gastric MALT lymphoma is often the result of an infection with *H. pylori*, the initial treatment is a triple therapy of two antibiotics combined with proton pump inhibitors (PPIs), typically given for two weeks. PPIs reduce the production of stomach acid to help prevent or heal ulcers. In about 90 percent of cases, these lymphomas go away following antibiotic and PPI treatment, although this may take several months. Most gastric MALT lymphomas are low-grade lesions that grow slowly and do not tend to spread to other places in the body. If the lymphoma relapses (disease returns after treatment) or becomes refractory (does not respond to treatment) after triple therapy, there are many additional treatment options available, including another round of antibiotic treatment, radiation, monoclonal antibodies targeting CD20 such as rituximab (Rituxan), alone or in combination with chemot

**NON-GASTRIC MALT LYMPHOMAS**

Non-gastric MALT lymphoma can appear in a variety of areas throughout the body. Therefore, treatment is usually based on the exact location and extent of spread. For MALT lymphoma of the eye, radiation therapy with or without antibiotic therapy usually has an excellent chance of response and patients can stay in remission for a long time. The antibiotic doxycycline has been shown to be effective in MZL that affects the area around the eye in certain areas of the world where infection with *Chlamydia psittaci* is commonly associated with OAL. Physicians may defer further treatment until symptoms appear, an approach called active surveillance, also known as watchful waiting (observation with no drug or radiation therapy given).
With this strategy, patients' overall health and disease are monitored through regular checkup visits and various evaluating procedures, such as laboratory and imaging tests. Active treatment is started if the patient begins to develop lymphoma-related symptoms or there are signs that the disease is progressing based on testing during follow-up visits. In localized cases, treatment typically includes radiation therapy. In rare cases, where radiation is not feasible, surgery can be used as an alternative. More advanced disease is usually treated with immunotherapy such as the monoclonal antibody rituximab (Rituxan), with or without chemotherapy. Common initial chemotherapy combination treatments are bendamustine (Treanda) plus rituximab (BR) or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), which are used to treat other slow-growing lymphomas such as follicular lymphoma.

**NODAL MZL**

Because nodal MZL is most often a slow-growing disease, physicians may adopt an active surveillance or watchful waiting approach until symptoms appear. When treatment is necessary, options include radiation therapy, chemotherapy and/or immunotherapy, and other treatments commonly used in other types of slow-growing lymphomas, such as follicular lymphoma.

**SPLENIC MZL**

Treatment is not always immediately necessary for splenic MZL. When treatment is deemed appropriate, several options exist. Some patients may receive a splenectomy (surgical removal of the spleen) while other patients may be given rituximab (Rituxan) with or without chemotherapy. In some cases, because of the association of this type of lymphoma with HCV, treatment of the HCV infection might result in the resolution of the lymphoma.

New treatments for all subtypes have been recently approved for relapsed disease. Ibrutinib (Imbruvica) was the first drug to be specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of MZL in these circumstances. It is used for the treatment of patients with MZL who require systemic (throughout the body) therapy and have received at least one prior anti-CD20–based therapy. Lenalidomide (Revlimid), is another oral medication that has been approved by the FDA for the treatment of patients with MZL who have received at least one prior therapy, and it is used in combination with rituximab (Rituxan), often referred to as R2 (R-squared). Recently, the multiple kinase inhibitor umbralisib (Ukoniaq) received approval for use in adult patients with relapsed or refractory MZL after at least one prior anti-CD20–based regimen.

For all subtypes, biosimilar therapies (drugs that are modeled after an existing biologic therapy) may be an option for patients who are taking rituximab. These include rituximab-abbs and rituximab-pvvr. For more information, patients should view the Biosimilars fact sheet on Lymphoma Research Foundation (LRF) website at lymphoma.org/publications and talk to their physician.

**TREATMENTS UNDER INVESTIGATION**

Several new drugs and drug combinations are being studied in clinical trials for MZL and other slow-growing lymphomas, including:

- Axicabtagene ciloleucel (Yescarta)
- Bortezomib (Velcade)
- Copanlisib (Aliqopa)
- Entospletinib
- Idelalisib (Zydelig)
- Ixazomib (Ninlaro)
- Nivolumab (Opdivo)
- Obinutuzumab (Gazyva)
- Panobinostat (Farydak)
- Parsaclisib
- Pembrolizumab (Keytruda)
- Ublituximab
- Venetoclax (Venclexta)
- Zandelisib (ME-401)
- Zanabrutinib

It is critical to remember that today's scientific research is continuously evolving. Treatment options may change as new treatments are discovered and current treatments are improved. Therefore, it is important that patients check with their physician or with the LRF for any treatment updates that may have recently emerged.

**CLINICAL TRIALS**

Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF's website (click here), and the Clinical Trials Search Request Form at lymphoma.org, talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing helpline@lymphoma.org.
**FOLLOW-UP**

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the treatments they have received. Medical tests (such as blood tests, computed tomography [CT] scans, and positron emission tomography [PET] scans) may be required at various times during remission to evaluate the need for additional treatment.

Some treatments can cause long-term side effects or late side effects, which can vary based on the duration and frequency of treatments, age, gender, and the overall health of each patient at the time of treatment. A physician will check for these side effects during follow-up care. Visits may become less frequent the longer the disease remains in remission.

Patients and their caregivers are encouraged to keep copies of all medical records and test results, as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app (lymphoma.org/mobileapp) can help patients manage this documentation.

**MOBILE APP**

*Focus On Lymphoma* is the first mobile application (app) that provides patients and caregivers comprehensive content based on their lymphoma subtype, including MZL, and tools to help manage their lymphoma such as, keep track of medications and blood work, track symptoms, and document treatment side effects. The *Focus On Lymphoma* mobile app is available for download for iOS and Android devices in the Apple App Store and Google Play. For additional information on the mobile app, visit FocusOnLymphoma.org. To learn more about any of these resources, visit our website at lymphoma.org, or contact the LRF Helpline at 800-500-9976 or helpline@lymphoma.org.

**LRF’S HELPLINE AND LYMPHOMA SUPPORT NETWORK**

A lymphoma diagnosis often triggers a range of feelings and concerns. In addition, cancer treatment can cause physical discomfort. The LRF Helpline staff members are available to answer your general questions about a lymphoma diagnosis and treatment information, as well as provide individual support and referrals to you and your loved ones. Callers may request the services of a language interpreter. A part of the Helpline is LRF’s one-to-one peer support programs, Lymphoma Support Network. This program connects patients and caregivers with volunteers who have experience with MZL, similar treatments, or challenges, for mutual emotional support and encouragement. Patients and loved ones may find this useful whether the patient is newly diagnosed, in treatment, or in remission.

**Resources**

LRF offers a wide range of free resources that address treatment options, the latest research advances, and ways to cope with all aspects of lymphoma and MZL. LRF also provides many educational activities, including our in-person meetings, podcasts, and webinars for people with lymphoma. For more information about any of these resources, visit our websites at lymphoma.org/MZL or lymphoma.org, or contact the LRF Helpline at (800) 500-9976 or helpline@lymphoma.org.

---

**LRF Appreciates the Expertise and Review of Our Editorial Committee:**

Leo I. Gordon, MD, FACP
Co-Chair
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Kristie A. Blum, MD
Emory University School of Medicine

John Allan
Weill Cornell Medicine

Jennifer E. Amengual, MD
Columbia University

Jonathon Cohen
Emory University School of Medicine

Alex Herrera, MD
City of Hope

Shana Jacobs, MD
Children’s National Hospital

Manali Kamdar, MD
University of Colorado

Peter Martin, MD,
Weill Cornell Medicine

Anthony Mato, MD
Memorial Sloan Kettering Cancer Center

Neha Mehta-Shah, MD, MSCI
Washington University School of Medicine in St. Louis

Pierluigi Porcu, MD
Thomas Jefferson University

Contact LRF:
Helpline: [800] 500-9976
Email: helpline@lymphoma.org
www.lymphoma.org

---

The Understanding Lymphoma series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.

© 2021 Lymphoma Research Foundation